Biomarkers Series US: Virtual

: Speakers

Speakers

15 - 16 October 2020 | PDT (UTC-7)

Biomarkers Series US: Virtual has now concluded. Registered delegates have access to the platform until 23rd October 2020. Please click here to be directed to the website for our in-person event, Biomarkers Series US, taking place 21 - 22 October 2021.

Attracting leading experts & the brightest minds in the industry to educate, inform and excite our attendees.

The following are confirmed speakers for the 2020 Series.

Akanksha Gupta

Head, Immunology Biomarker Solutions Center

Covance

Alekhya Pochiraju

Biomarker Operations Manager, Global Product Development

Genentech

Alwin Schuller

Director, Team Lead, Oncology

AstraZeneca

Anand Giddabasappa

Senior Principal Scientist

Pfizer, Inc.

Armin Sepp

Scientific Leader and GSK Fellow

GlaxoSmithKline

Brian Dougherty

Executive Director, Translational Medicine, Oncology R&D

AstraZeneca

Carl de Moor

Executive Director and Head, Global Real World Evidence Strategy and Analytics

Biogen

Christopher Helsen

Director, R&D and Head, Platform Development

Triumvira Immunologics

Craig Chappell

Senior Scientist, Immunology Discovery

Merck & Co.

Daniela Cipolletta

Lab head, Investigator III Immuno-Oncology

Novartis

Darrell Borger

Associate Director, Translational Sciences, Head, Integrated Translational Technologies Oncology Drug Development Unit

Takeda

Dave Hoon

Professor and Director

John Wayne Cancer Institute

David Miklos

Associate Professor

Stanford University

Dipen Sangurdekar

Director, Bioinformatics, Data Science

Bluebird bio

Elizabeth Somers

Director Diagnostic Development

Eisai

Ellie Corigliano

Global Director Medical Affairs, Oncology; Thoracic Malignancies Biomarkers & Diagnostics

Merck & Co. Inc.

Emily Thrash

Scientist II, Center for Immuno-Oncology - Immune Assessment Laboratory

Dana-Farber Cancer Institute

Emmett Schmidt

Scientific Associate Vice President

Merck & Co.

Gary Kelloff

Special Advisor and Biomarkers Consortium Cancer Steering Committee Co-Chair

National Institute of Health

George Poste

Chief Scientist, Complex Adaptive Systems

Arizona State University

Glynn Dennis Jr.

Senior Director, Data Science

AstraZeneca

Graham Jones

Director of Innovation; Head - Digital Solutions Team

Novartis

Hartmuth Kolb

Vice President, Head of Neuroscience Biomarkers & JRD Global Imaging

Janssen

Heather Llewellyn

Senior Scientist, Biomarkers, Drug Safety R&D

Pfizer

Holly Soares

Head of Precision Medicine, Vice President

Pfizer

Hong Liu

Associate Scientific Director

Takeda

Jakob Dupont

Global Head of Research and Development

Atara Biotherapeutics

Janica Wong

Senior Scientist, Translational Pathology

Merck & Co.

Jason Hipp

Senior Director, Translational Medicine; Head of Pathology Data Science & Innovation

AstraZeneca

Jennifer Burkey

Scientific Director, Predictive Safety Testing Consortium

C-Path Institute

Joanne Imperial

Vice President, Clinical Research

Blade Therapeutics

Joe Benoun

Scientist

Kite, A Gilead Company

Joseph Dolina

Senior Scientist

Pfizer

Kader Thiam

Senior Vice President Discovery and Preclinical Models & Services

genOway

Karin Jooss

Chief Scientific Officer

Gritstone Oncology

Klaus Romero

Executive Director of Clinical Pharmacology and Quantitative Medicine

C-Path Institute

Kristin Blouch

Director, Head of RWE & Molecular Disease Characterisation, Experimental Medicine Unit

GlaxoSmithKline

Laurence Cooper

Chief Executive Officer

Ziopharm Oncology

Majid Ghoddusi

Senior Director, Clinical Biomarkers

Poseida Therapeutics

Martin Tolar

Chief Executive Officer

Alzheon

Matthew Davison

Director

Sanofi

Melanie Patterson

Principal Research Scientist II

AbbVie

Michael Streit

MD, MBA, Vice President, Clinical Development, Oncology R&D

GlaxoSmithKline

Mohini Rajasagi

Director, Oncology Translational Science and Clinical Biomarkers

Merck & Co.

Nan Doyle

Associate Director and Lead, Rare Diseases

Takeda

Nathalie Fiaschi

Director Oncology & Angiogenesis

Regeneron Pharmaceuticals

Nathan Hedrick

Director, Clinical Flow Cytometry

Bristol-Myers Squibb

Nuzhat Pathan

Director Early Development, Translational and Immuno-Oncology

Pfizer

Paul Moore

Vice President, Cell Biology and Immunity

Macrogenics

Petar Jelinic

Director, Oncology Translational Science and Clinical Biomarkers

Merck & Co.

Qing Kang-Fortner

Associate Director

Syros Pharmaceuticals

Rajiv Raja

Director, Translational Medicine Oncology and Pharmacogenomics

AstraZeneca

Raquel Deering

Associate Director, Oncology & Angiogenesis

Regeneron Pharmaceuticals

Ravi Madan

Clinical Director, Genitourinary Malignancies Branch

National Cancer Institute, NIH

Richard Trauger

Senior Director Translational Medicine

Viracta Therapeutics

Sandrine Miller-Montgomery

Executive Director of the Center for Microbiome Innovation, Professor of Practice, Bioengineering

UC San Diego

Sarah Harris

Senior Director, Translational Medicine

Celgene

Shahram Lavasani

Chief Executive Officer

ImmuneBio AB

Shahram Salek-Ardakani

Senior Director, Cancer Immunology

Pfizer

Shiaw-Yih (Phoebus) Lin

Professor and Deputy Chair, Chief, Section of Systems and Translational DNA Repair, Department of Systems Biology

The University of Texas MD Anderson Cancer Center

Simi Ahmed

Head of Immune Therapy

JDRF

Stanley Frankel

Senior Vice President, Cellular Therapy Development

Bristol-Myers Squibb

Stephen Miller

Vice President, Translational Medicine

Blueprint Medicines

Tapan Nayak

Director, Translational Imaging Biomarkers

Merck & Co.

Virna Cortez-Retamozo

Lab Head, Senior Scientist, Oncology-Pharmacology

Sanofi

Volker Schellenberger

President and Chief Technology Officer

Amunix Pharmaceuticals

Wen Luo

Chief Executive Officer and Chief Scientific Officer

Denovo Biopharma

Xiaoying Chen

Director, Early Clinical Research

Pfizer

Xuemei Zhao

Principal Scientist

Merck